Panitumumab outcome by tumour location analysis
Study limitations
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
Unplanned, retrospective exploratory analysis
Potential imbalances between treatment subgroups due to
lack of randomisation
HR adjusted for selected baseline factors
Low numbers of patients with right-sided tumours
No data on biomarkers beyond
RAS
and
BRAF
